Related references
Note: Only part of the references are listed.JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan
Yoko Edahiro et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
MicroRNAs in myeloproliferative neoplasms
Huichun Zhan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
Daniel J. DeAngelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
Tomoya Muto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells
Michael R. Copley et al.
NATURE CELL BIOLOGY (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis
Miao Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties
Jinsuke Nishino et al.
ELIFE (2013)
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi
BLOOD (2012)
Efficacy of vorinostat in a murine model of polycythemia vera
Hajime Akada et al.
BLOOD (2012)
Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria
Yoshiko Murakami et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines
Pietro Di Fazio et al.
EXPERIMENTAL CELL RESEARCH (2012)
Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes
Hideyuki Oguro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling
Yang Zong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
3′UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice
Kazuhiko Ikeda et al.
BLOOD (2011)
Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging
Seunghee Lee et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
DNA Methylation and Demethylation in Mammals
Zhao-xia Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
Juan Li et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
Omar Abdel-Wahab et al.
CANCER RESEARCH (2010)
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Yongchao Wang et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
Warren Fiskus et al.
CANCER BIOLOGY & THERAPY (2009)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Hmga2 Promotes Neural Stem Cell Self-Renewal in Young but Not Old Mice by Reducing p16Ink4a and p19Arf Expression
Jinsuke Nishino et al.
CELL (2008)
Aberrant expression of microRNA in polycythemia vera
Hana Bruchova et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Oncogenic HMGA2: short or small?
Andrew R. J. Young et al.
GENES & DEVELOPMENT (2007)
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
Yong Sun Lee et al.
GENES & DEVELOPMENT (2007)
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation
Christine Mayr et al.
SCIENCE (2007)
Molecular profiling of CD34(+) cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
Paola Guglielmelli et al.
STEM CELLS (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone
Kazuhiko Ikeda et al.
EXPERIMENTAL HEMATOLOGY (2007)
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies
MD Odero et al.
LEUKEMIA (2005)
Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer
R Sgarra et al.
FEBS LETTERS (2004)
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia
J Andrieux et al.
GENES CHROMOSOMES & CANCER (2004)
Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia
DH Christiansen et al.
LEUKEMIA (2003)
Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene
M Ferguson et al.
NUCLEIC ACIDS RESEARCH (2003)
Share Paper
